Refine by
T Cells Suppliers & Manufacturers
217 companies found
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and ...
based inSan Diego, CALIFORNIA (USA)
Invivoscribe is a global leader in molecular diagnostics, providing a comprehensive range of standardized, CE-marked in vitro diagnostic products and companion diagnostics for hematology-oncology. The company's offerings include research use only ...
based inSan Francisco, CALIFORNIA (USA)
Cypre is a biotechnology company dedicated to overcoming therapeutic resistance for cancer patients. Our 3D Tumor Model Platform engineers the tumor microenvironment in vitro at high throughput for drug efficacy and MOA studies. We are now applying ...
based inPleasanton, PENNSYLVANIA (USA)
10x Genomics is building tools for scientific discovery that reveal and address the true complexities of biology and disease. 10x Genomics products have been adopted by researchers around the world, including all of the top 100 global research ...
Multiomic profiling of immune diversity, cell by cell. Chromium Single Cell Immune Profiling provides a multiomic solution to your immunology questions. Analyze full-length, paired ...
based inSherman Oaks, CALIFORNIA (USA)
T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...
T cell engineering with TCRs is a growing area of immuno-oncology with recent breakthroughs in clinical settings. The T-Cure approach involves identifying and isolating a high avidity TCR which ...
based inLondon, UNITED KINGDOM
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic ...
They are personalized with a candidate companion diagnostic test (CDx). In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high ...
based inHayward, CALIFORNIA (USA)
We are a biotech startup in the San Francisco Bay Area founded in February 2017. We focus on developing complex antibodies with enhanced efficacy, safety, and manufacturability features against difficult-to-treat diseases including cancer, ...
1D antibody sequence analysis service with licensed software and in-house ...
based inColumbia, MARYLAND (USA)
Hemagen Inc. was founded in 1985 by a group of scientists from the Boston University School of Medicine. Hemagen's mission is to offer high quality diagnostic test kits in user friendly formats. We continue to the highest quality gold standard test ...
based inDallas, TEXAS (USA)
Lupagen is a privately held early stage biotech company developing first-in-class bedside enabled cell & gene therapies (CAR-T cell, gene editing and immunotherapy products) based on their patent-pending bedside point-of-care C and GT production and ...
based inMorrisville, NORTH CAROLINA (USA)
Istari Oncology, Inc., is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy ...
The tumor environment contains all the ingredients needed to mount an anticancer immune response—tumor antigens, antigen presenting cells (APCs, including tumor-associated macrophages [TAMs] and dendritic ...
based inRizhao, CHINA
Shandong Jiejing Group Corporation (hereinafter referred to as the company) was founded in 1968 and is now an enterprise group integrating food additive, cosmetic ingredients, dental impression material, marine biology, health products, textile ...
based inShirley, NEW YORK (USA)
Creative Biogene provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. Creative Biogene holds a leadership position in the global market and is committed to improving the human ...
The major vectors for gene therapy in basic research and clinical study are viruses, because of the high transfer efficiency, the relatively short time needed to reach the clinically necessary numbers of cultured T ...
based inPhiladelphia, PENNSYLVANIA (USA)
With extensive experience optimising processes for analytical, production and R&D laboratories across multiple industries and regulatory environments, we provide consistent, quality informatics solutions. We operate on a truly global basis, serving ...
Gibco CTS OpTmizer Pro SFM is a novel medium, developed for the growth and expansion of human T lymphocytes (e.g., CD4+, CD8+, polyclonal cells, or antigen specific T cells) used in ...
based inAmsterdam, NETHERLANDS
Sanquin employs people working in many different disciplines, including donor assistants, doctors, pharmacists, researchers, laboratory technicians and production staff. Sanquin has a Supervisory Board responsible for the overall monitoring of the ...
Our proprietary technology for UV-induced MHC-peptide exchange is ideally suited for high-throughput screening of peptide-binding to the MHC class I complexes. Moreover, combinatorial coding enables fast finding of relevant peptide-specific ...
based inSeattle, WASHINGTON (USA)
We are a pre-clinical-stage biotech company combining protein design and screening to create novel biologics for serious unmet medical needs. Using this approach, we are developing an early pipeline of innovative programs in multiple indications. ...
The IL-2 pathway influences critical aspects of both immune stimulation and immune regulation, through the development and expansion of regulatory T cells ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics’ TCER molecules can be produced and purified utilizing established processes to manufacture ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
Based on specific size and bio-distribution characteristics, the AIM™ nanoparticles have the ability to engage antigen-specific T cell populations at multiple sites in the body (lymph node, lymphatic system, ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Novel transgene combinations. Our research team are developing a suite of viral vectors with new and innovative transgene ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
based inRensselaer, NEW YORK (USA)
Taconic Biosciences has been a leading provider of research models for over 65 years. Through all six decades, we've had a singular mission—to accelerate advancements in human health by providing our customers with the best animal model solutions. ...
The Lck-Cre transgenic mouse uses the proximal promoter of the Lck (lymphocyte protein tyrosine kinase) gene, which is first expressed early in thymocyte development at the double negative stage. After T cells fully ...
